S&P calls Euro-Pharma 'recession resistant'

Standard & Poor's likes European pharma companies. It really, really likes them. In a new report, the ratings agency says that Europe's pharma sector "appears to be barely scathed by the economic recession." How so? The drugmakers tend to be growing in--you guessed it--emerging markets. "Medicines in developed markets are mostly financed by health insurance schemes and their market prospects are swelled by growing populations with increasingly unhealthy lifestyles," said S&P's credit analyst Olaf Toelke.

That emerging-market strength will help the European companies offset sluggish growth in the U.S., the report says. Among the companies with the strongest positions in developing countries, according to S&P are Bayer, Sanofi-Aventis, and AstraZeneca, partly because of their early entry to those markets and partly because of "geographic proximity."

If Euro-Pharma gets too enamored with M&A, however, S&P's love affair with the industry could fade. "[W]e see a heightened risk that companies could adopt more aggressive financial policies, which could potentially result in negative rating actions," Toelke said. To wit: the recent focus on mergers and acquisitions by large drugmakers in the U.S., the report states. Hmm. A backlash against the mega-merger? What do you think?

- read the S&P report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.